BDSXBiodesix, Inc.

$151M

Q4 2025 Earnings

Healthcare Medical - Diagnostics & Research

Income Statement

Revenue

$29M+40.8% YoY

Gross Profit

$24M83.0% margin

Operating Income

-$2M-6.8% margin

Net Income

-$4M-13.8% margin

EPS (Diluted)

$-0.49

QoQ Revenue Growth

+32.1%

Cash Flow

Operating Cash Flow

$778,000

Free Cash Flow

$629,000

Stock-Based Comp.

$1M

Balance Sheet

Total Assets

$87M

Total Liabilities

$90M

Stockholders' Equity

-$2M

Cash & Equivalents

$19M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$29M	$20M	+40.8%
Gross Profit	$24M	$16M	+48.4%
Operating Income	-$2M	-$7M	+70.4%
Net Income	-$4M	-$8M	+51.8%

Revenue Segments

Diagnostic Tests

$25M87%

Development Services

$4M13%

BDSX Q4 2025 Earnings — Biodesix, Inc. Revenue & Financial Results | Market Cap Arena